F-star Therapeutics Stock News

F-star Therapeutics, Inc. (NASDAQ:FSTX) Research analysts at William Blair lifted their FY2021 earnings estimates for F-star Therapeutics in a research report issued on Wednesday, November 10th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($1.76) per share for the year, up from their prior forecast of ($3.22). William []

F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript

Dr. Michelle Morrow to present on F-star's Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next ge

F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q2 2021 Results - Earnings Call Transcript

F-star Therapeutics (FSTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gen

Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination with Atezolizumab Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combinatio

Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus Conference Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare C

CAMBRIDGE, England--(BUSINESS WIRE)--IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ: FSTX), has d

Two new sample breakout stocks for Week 25 with better than 10% short-term upside potential. This past week, the peak gains were in SOL +9.3% and INBX +7.3% with the Market and S&P 500 Momentum Gauges

F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical compa